摘要
目的探讨艾司西酞普兰在卒中后抑郁焦虑共病治疗中的临床效果;方法从我院2012年3月至2014年3月收治的卒中后抑郁焦虑共病患者中选取82例为观察对象,随机分为观察组与对照组,每组41例,对照组帕罗西汀治疗,观察组行艾司西酞普兰治疗,观察两组患者治疗前后汉密尔顿焦虑量表(HAMA)评分及汉密尔顿抑郁量表(HAMD)评分,并分析不良反应情况;结果两组患者治疗前HAMA、HAMD均无明显差异(P>0.05),观察组HAMA、HAMD评分治疗4周后明显低于对照组,差异具有统计学意义(P<0.05),两组患者不良反应无明显差异(P>0.05);结论卒中后抑郁焦虑共病患者使用艾司西酞普兰治疗,可有效缓解焦虑、抑郁症状,提高患者生活质量,同时具有较高安全性,值得临床推广运用。
Objective To investigate the clinical effect of Ai Sciplan in the post - stroke comorbid anxiety and depression in the treatment of stroke; Methods From March March to 2014 2012 in our hospital were later comorbid anxiety and depression in patients selected 82 cases as the observation object, randomly divided into observation group and control group,41 cases in each group,control group,Pa Rossi Dean treatment,observation group received escitalopram treatment,two groups were observed before and after treatment in patients with Hamilton Anxiety Scale （HAMA） score and the Hamilton Depression Scale （HAMD） score,and analyze the adverse circumstances; Results There was no significant difference between the two groups of patients before HAMA treatment,HAMD （P〉0.05）,were observed in group HAMA,HAMD score 4 weeks after treatment was significantly lower than the control group,with significant difference （P〈0.05）,no significant difference between the two groups of patients with adverse reactions （P〉0.05）; Conclusion Post stroke comorbid anxiety and depression of patients using the Ai Sciplan treatment,can effectively al eviate the anxiety,depressive symptoms,improve the quality of life of patients,and has higher security,is worthy of clinical application.
出处
《中国卫生标准管理》
2015年第4期99-100,共2页
China Health Standard Management
